chronic autoimmune diseases
J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis
Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes
J&J’s Icotyde approved by US FDA for plaque psoriasis
Plaque psoriasis affects over 125 million people worldwide
J&J’s nipocalimab gets FDA Fast Track designation for lupus
The autoimmune disease affects approximately three to five million people globally
Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma
Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable
Novartis’ ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
Approximately half of those with Sjögren’s disease are thought to be undiagnosed
Johnson & Johnson’s Rybrevant shows positive effects in difficult-to-treat colorectal cancer
Colorectal cancer accounts for around 10% of all cancer cases globally, with an increase in diagnoses in younger people
J&J receives positive NICE recommendation for multiple myeloma treatment
The treatment is approved for use within the NHS in England and Wales
Johnson & Jonson secures FDA approval for multiple myeloma treatment
Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results
Novartis presents new positive data for rheumatic autoimmune disease treatment
Patient outcome benefits were observed in two ongoing phase 3 trials
Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis
Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis
John Morikis joins Johnson & Johnson’s board of directors
Morikis was previously Chairman, President and CEO at Sherwin-Williams
Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis
Approximately 125 million people globally are living with some form of psoriasis